A Phase 1 interventional study of Maraviroc (Part 1) and Maraviroc (Part 2) in Healthy Subjects, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This will be an open-label, parallel group, multiple dose study in approximately 48 healthy male or female subjects of African American and Caucasian self-reported race, to assess the effect of CYP3A5 genotype on the PK of MVC and CYP3A5-derived metabolites. Maraviroc and CYP3A5-derived metabolite PK will also be compared between African-Americans and Caucasians in subjects carrying two copies of the dysfunctional CYP3A5 alleles (*3, *6, and/or *7).
This will be an open-label, parallel group, multiple dose study in approximately 48 healthy male or female subjects of African American and Caucasian self-reported race, to assess the effect of CYP3A5 genotype on the PK of MVC and CYP3A5-derived metabolites. Maraviroc and CYP3A5-derived metabolite PK will also be compared between African-Americans and Caucasians in subjects carrying two copies of the dysfunctional CYP3A5 alleles (*3, *6, and/or *7).
Dysfunctional genetic variants for CYP3A5, CYP3A4 and SLCO1B1 will be genotyped for subjects who participate in the pre-screening. Subjects who meet the inclusion/exclusion criteria for study participation will be placed into the study cohorts based on race and the number of functional (*1) and dysfunctional CYP3A5 alleles (*3, *6, and *7) CYP3A5 alleles.
Cohort 1 (n=12; African-American): No CYP3A5*1 alleles (poor metabolizer). Cohort 2 (n=12; African-American): One CYP3A5*1 allele (intermediate metabolizer).
Cohort 3 (n=12; African-American): Two CYP3A5*1 alleles (extensive metabolizer).
Cohort 4 (n=12; Caucasian): No CYP3A5*1 alleles (poor metabolizer).
Study Treatments:
Part 1 Days 1-5: Maraviroc 300 mg BID in fasted state (AM dose only on Day 5). Part 2 (Cohorts 1 and 3 only) Days 1-10: Maraviroc 150 mg QD plus darunavir/cobicistat 800/150 mg QD with food.
Pharmacokinetics of MVC, PF-6857639, PF-6857640 and other hydroxylated metabolites with formation mediated by CYP3A5 (if present) will be assessed on Part 1, Day 5 and Part 2, Days 10-11. Blood samples will be collected for a full PK profile.
Subjects will be confined to the Clinical Research Unit (CRU) the day prior to dosing on Day 1 (Day 0) and discharged on Part 1, Day 6 and on Part 2, Day 11 (Cohorts 1 and 3 only). Subjects enrolled into Cohorts 1 and 3 may be confined to the CRU without the need to be discharged between Part 1 and Part 2.
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
African-Americans with No CYP3A5\*1 alleles (poor metabolizer)
Drug: Maraviroc (Part 1) · Drug: Maraviroc (Part 2) · Drug: Darunavir/cobicistat (Part 2)
African-Americans with One CYP3A5\*1 allele (intermediate metabolizer)
Drug: Maraviroc (Part 1)
African-Americans with Two CYP3A5\*1 alleles (extensive metabolizer)
Drug: Maraviroc (Part 1) · Drug: Maraviroc (Part 2) · Drug: Darunavir/cobicistat (Part 2)
Caucasians with No CYP3A5\*1 alleles (poor metabolizer)
Drug: Maraviroc (Part 1)
300 mg twice daily x 5 days
Also known as: Selzentry
150 mg once daily x 10 days
Also known as: Selzentry
Drug page: Cobicistat mixture with darunavir
800/150 mg once daily x 10 days
Also known as: Prezcobix
Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc
AUC (0-12) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 2: Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) of Maraviroc
AUC (0-24) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours post-dose.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10
Part 1: Metabolite to Parent Ratio for Area Under the Concentration-Time Curve From Time 0 to 12 Hours for Maraviroc and Its Metabolites (MRAUC12)
MRAUC12 is the ratio of AUC12 of maraviroc to AUC12 of maraviroc's metabolites. Metabolites of Maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573. AUC12 is the area under the plasma concentration-time profile from time 0 to 12 hours post-dose.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 1: Average Plasma Concentration (Cavg) of Maraviroc
Cavg is the average plasma concentration of maraviroc during the 0 to 12 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 12 hours (AUC \[0-12\]) divided by 12.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 2: Average Plasma Concentration (Cavg) of Maraviroc
Cavg is the average plasma concentration of maraviroc during the 0 to 24 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 24 hours (AUC \[0-24\]) divided by 24.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10
Part 1: Maximum Observed Plasma Concentration (Cmax) of Maraviroc
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 2: Maximum Observed Plasma Concentration (Cmax) of Maraviroc
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10
Part 1: Plasma Concentration of Maraviroc at 12 Hours Post-dose
Time frame: 12 hours post-dose on Day 5
Part 2: Plasma Concentration of Maraviroc at 24 Hours Post-dose
Time frame: 24 hours post-dose on Day 10
Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10
Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Metabolites of Maraviroc
AUC (0-12) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose. Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 1: Average Plasma Concentration (Cav) of Metabolites of Maraviroc
Cavg is the average plasma concentration of metabolites of maraviroc during the 0 to 12 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 12 hours (AUC \[0-12\]) divided by 12. Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 1: Maximum Observed Plasma Concentration (Cmax) of Metabolites of Maraviroc
Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metabolites of Maraviroc
Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Part 1: Plasma Concentration of Metabolites of Maraviroc at 12 Hour Post-dose
Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
Time frame: 12 hour post-dose on Day 5
Part 1: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 days that were absent before treatment or that worsened relative to pre-treatment state.
Time frame: Baseline up to end of study (up to 6 days)
Part 2: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 11 days that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to end of study (up to 11 days)
Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities
Criteria for clinically significant vital sign abnormalities included supine/sitting pulse rate of less than (\<) 40 beats per minute (bpm) or greater than (\>)120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine systolic blood pressure (SBP) and standing SBP of \<90 millimeter of mercury (mm Hg), greater than or equal to (\>=) 30 mm Hg, supine diastolic blood pressure (DBP) and standing DBP of \<50 mm Hg, \>=20 mm Hg.
Time frame: Baseline up to Day 6
Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities
Criteria for clinically significant vital sign abnormalities included supine/sitting pulse rate of \<40 bpm or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine SBP and standing SBP of \<90 mm Hg, \>=30 mm Hg, supine DBP and standing DBP of \<50 mm Hg, \>=20 mm Hg.
Time frame: Baseline up to Day 11
Part 1: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
Criteria for ECG abnormalities: Maximum PR interval of \>=300 milliseconds (msec), maximum QRS interval \>=140 msec, maximum QTCF interval (Fridericia's correction) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, maximum increase of \>=25 percent for baseline values of \>200 msec and \>=50 percent for baseline values of less than or equal to (\<=) 200 msec for PR interval, maximum increase from baseline of \>=50 percent for QRS interval, maximum increase from baseline of \>=30 msec to \<60 msec and maximum increase from baseline of \>60 msec in QTCF interval (Fridericia's Correction).
Time frame: Baseline up to Day 6
Part 2: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
Criteria for ECG abnormalities: Maximum PR interval of \>=300 msec, maximum QRS interval \>=140 msec, maximum QTCF interval (Fridericia's correction) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, maximum increase of \>=25 percent for baseline values of \>200 msec and \>=50 percent for baseline values of \<=200 msec for PR interval, maximum increase from baseline of \>=50 percent for QRS interval, maximum increase from baseline of \>=30 msec to \<60 msec and maximum increase from baseline of \>60 msec in QTCF interval (Fridericia's Correction).
Time frame: Baseline up to Day 11
Part 1: Number of Participants With Laboratory Abnormalities
Criteria: Hemoglobin; hematocrit; red blood cell count: \<0.8\*lower limit of normal, (LLN), mean corpuscular volume; mean corpuscular hemoglobin concentration; mean platelet volume:\<0.9\*LLN or \>1.1\* upper limit of normal (ULN), platelet: \<0.5\*LLN or \>1.75\*ULN, white blood cells \<0.6\*LLN or \>1.5\*ULN, lymphocyte; neutrophil: \<0.8\*LLN or \>1.2\*ULN, basophil; eosinophil; monocyte:\>1.2\*ULN, bilirubin (total, direct, indirect) \>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase:\>3.0\*ULN, total protein; albumin:\<0.8\*LLN or \>1.2\*ULN; creatinine: \>1.3\*ULN, uric acid\>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride; calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN, glucose \<0.6\*LLN or \>1.5\*ULN, urine specific gravity \<1.003, urine pH \<4.5 or \>8, urine glucose or ketones (qualitative) \>=1, urine protein; urine blood/hemoglobin \>=1, urobilinogen; bilirubin; nitrite; leukocyte esterase \>=1.
Time frame: Baseline up to Day 6
Part 2: Number of Participants With Laboratory Abnormalities
Criteria: Hemoglobin; hematocrit; red blood cell count: \<0.8\*LLN, mean corpuscular volume; mean corpuscular hemoglobin concentration; mean platelet volume: \<0.9\*LLN or \>1.1\*ULN, platelet: \<0.5\*LLN or \>1.75\*ULN, white blood cells \<0.6\*LLN or \>1.5\*ULN, lymphocyte; neutrophil: \<0.8\*LLN or \>1.2\*ULN, basophil; eosinophil; monocyte: \>1.2\*ULN, bilirubin (total, direct, indirect) \>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase: \>3.0\*ULN, total protein; albumin: \<0.8\*LLN or \>1.2\*ULN; creatinine: \>1.3\*ULN, uric acid \>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride; calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN, glucose \<0.6\*LLN or \>1.5\*ULN, urine specific gravity \<1.003, urine pH \<4.5 or \>8, urine glucose or ketones (qualitative) \>=1, urine protein; urine blood/hemoglobin \>=1, urobilinogen; bilirubin; nitrite; leukocyte esterase \>=1.
Time frame: Baseline up to Day 11
| Milestone | Part 1 and Part 2: Cohort 1 -No CYP3A5*1 Alleles | Part 1: Cohort 2 - One CYP3A5*1 Allele | Part 1 and 2: Cohort 3 - Two CYP3A5*1 Alleles | Part 1: Cohort 4 - No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Started | 11 | 12 | 12 | 12 |
| Completed | 11 | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1 and Part 2: Cohort 1 -No CYP3A5*1 Alleles | Part 1: Cohort 2 - One CYP3A5*1 Allele | Part 1 and 2: Cohort 3 - Two CYP3A5*1 Alleles | Part 1: Cohort 4 - No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Started | 11 | 0 | 12 | 0 |
| Completed | 11 | 0 | 12 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
AUC (0-12) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose.
| nanogram*hour per milliliter (ng*hr/mL) | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc | 3441 ± 24 | 2954 ± 23 | 2181 ± 27 | 2947 ± 23 |
AUC (0-24) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours post-dose.
| ng*hr/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| Part 2: Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) of Maraviroc | 4413 ± 20 | 3645 ± 25 |
MRAUC12 is the ratio of AUC12 of maraviroc to AUC12 of maraviroc's metabolites. Metabolites of Maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573. AUC12 is the area under the plasma concentration-time profile from time 0 to 12 hours post-dose.
| ratio | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| PF-6857639 | 0.02172 ± 31 | 0.03564 ± 27 | 0.04312 ± 32 | 0.01585 ± 24 |
| PF-6857640 | 0.02577 ± 11 | 0.02621 ± 27 | 0.02797 ± 32 | 0.02338 ± 14 |
| PF-06927572 | 0.02766 ± 19 | 0.02908 ± 35 | 0.02795 ± 37 | 0.02774 ± 29 |
| PF-06927573 | 0.02048 ± 14 | 0.02427 ± 38 | 0.02040 ± 27 | 0.02099 ± 21 |
Cavg is the average plasma concentration of maraviroc during the 0 to 12 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 12 hours (AUC \[0-12\]) divided by 12.
| nanogram per milliliter (ng/mL) | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Part 1: Average Plasma Concentration (Cavg) of Maraviroc | 286.8 ± 24 | 246.2 ± 23 | 181.6 ± 27 | 245.8 ± 23 |
Cavg is the average plasma concentration of maraviroc during the 0 to 24 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 24 hours (AUC \[0-24\]) divided by 24.
| ng/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| Part 2: Average Plasma Concentration (Cavg) of Maraviroc | 184.1 ± 20 | 151.7 ± 25 |
| ng/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Part 1: Maximum Observed Plasma Concentration (Cmax) of Maraviroc | 863.9 ± 29 | 754.0 ± 29 | 529.0 ± 34 | 731.0 ± 33 |
| ng/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| Part 2: Maximum Observed Plasma Concentration (Cmax) of Maraviroc | 633.6 ± 37 | 432.9 ± 53 |
| ng/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Part 1: Plasma Concentration of Maraviroc at 12 Hours Post-dose | 59.84 ± 36 | 63.09 ± 27 | 45.32 ± 35 | 63.10 ± 24 |
| ng/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| Part 2: Plasma Concentration of Maraviroc at 24 Hours Post-dose | 56.56 ± 20 | 56.34 ± 30 |
| hour | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc | 3.00 (2.00 to 4.00) | 2.00 (0.500 to 3.00) | 2.00 (0.517 to 4.00) | 2.01 (0.500 to 3.05) |
| hour | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc | 3.00 (1.07 to 6.00) | 3.02 (1.00 to 6.02) |
AUC (0-12) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose. Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
| ng*hr/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| PF-6857639 | 77.09 ± 32 | 108.7 ± 44 | 96.98 ± 29 | 48.24 ± 32 |
| PF-6857640 | 91.42 ± 22 | 79.92 ± 44 | 62.86 ± 26 | 71.15 ± 23 |
| PF-06927572 | 98.14 ± 23 | 88.63 ± 49 | 62.80 ± 28 | 84.32 ± 33 |
| PF-06927573 | 72.67 ± 28 | 73.92 ± 53 | 45.86 ± 27 | 63.88 ± 28 |
Cavg is the average plasma concentration of metabolites of maraviroc during the 0 to 12 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 12 hours (AUC \[0-12\]) divided by 12. Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
| ng/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| PF-6857639 | 6.420 ± 32 | 9.049 ± 44 | 8.074 ± 29 | 4.018 ± 32 |
| PF-6857640 | 7.615 ± 22 | 6.658 ± 44 | 5.239 ± 26 | 5.930 ± 23 |
| PF-06927572 | 8.179 ± 23 | 7.383 ± 49 | 5.232 ± 28 | 7.029 ± 33 |
| PF-06927573 | 6.056 ± 28 | 6.165 ± 53 | 3.821 ± 27 | 5.323 ± 28 |
Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
| ng/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| PF-6857639 | 18.14 ± 23 | 24.18 ± 55 | 20.52 ± 34 | 11.22 ± 37 |
| PF-6857640 | 21.95 ± 28 | 18.96 ± 56 | 15.00 ± 30 | 16.48 ± 28 |
| PF-06927572 | 22.88 ± 18 | 20.67 ± 58 | 15.31 ± 32 | 19.91 ± 35 |
| PF-06927573 | 17.39 ± 32 | 17.64 ± 66 | 10.86 ± 34 | 15.27 ± 35 |
Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
| hour | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| PF-6857639 | 3.00 (1.00 to 4.00) | 2.00 (0.500 to 3.00) | 2.00 (0.533 to 4.00) | 3.00 (0.500 to 4.00) |
| PF-6857640 | 3.00 (1.00 to 4.00) | 2.00 (0.500 to 3.02) | 2.00 (0.533 to 4.00) | 3.00 (1.00 to 4.00) |
| PF-06927572 | 3.00 (1.00 to 4.00) | 2.00 (0.500 to 3.00) | 1.52 (0.500 to 4.00) | 3.00 (1.00 to 4.00) |
| PF-06927573 | 3.00 (1.00 to 4.00) | 2.00 (0.500 to 3.00) | 2.00 (0.567 to 4.00) | 3.00 (1.00 to 4.00) |
Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.
| ng/mL | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| PF-6857639 | 0.6249 ± 7399 | 2.748 ± 43 | 2.226 ± 32 | 0.9213 ± 38 |
| PF-6857640 | 0.6290 ± 7164 | 1.658 ± 40 | 1.134 ± 29 | 1.300 ± 33 |
| PF-06927572 | 0.6242 ± 7051 | 1.752 ± 45 | 1.071 ± 29 | 1.385 ± 40 |
| PF-06927573 | 0.5396 ± 6283 | 1.629 ± 55 | 0.8550 ± 26 | 1.175 ± 32 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 days that were absent before treatment or that worsened relative to pre-treatment state.
| participants | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| AEs | 3 | 0 | 0 | 3 |
| SAEs | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 11 days that were absent before treatment or that worsened relative to pretreatment state.
| participants | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| AEs | 2 | 1 |
| SAEs | 0 | 0 |
Criteria for clinically significant vital sign abnormalities included supine/sitting pulse rate of less than (\<) 40 beats per minute (bpm) or greater than (\>)120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine systolic blood pressure (SBP) and standing SBP of \<90 millimeter of mercury (mm Hg), greater than or equal to (\>=) 30 mm Hg, supine diastolic blood pressure (DBP) and standing DBP of \<50 mm Hg, \>=20 mm Hg.
| participants | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities | 0 | 0 | 0 | 0 |
Criteria for clinically significant vital sign abnormalities included supine/sitting pulse rate of \<40 bpm or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine SBP and standing SBP of \<90 mm Hg, \>=30 mm Hg, supine DBP and standing DBP of \<50 mm Hg, \>=20 mm Hg.
| participants | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities | 0 | 0 |
Criteria for ECG abnormalities: Maximum PR interval of \>=300 milliseconds (msec), maximum QRS interval \>=140 msec, maximum QTCF interval (Fridericia's correction) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, maximum increase of \>=25 percent for baseline values of \>200 msec and \>=50 percent for baseline values of less than or equal to (\<=) 200 msec for PR interval, maximum increase from baseline of \>=50 percent for QRS interval, maximum increase from baseline of \>=30 msec to \<60 msec and maximum increase from baseline of \>60 msec in QTCF interval (Fridericia's Correction).
| participants | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Part 1: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 |
Criteria for ECG abnormalities: Maximum PR interval of \>=300 msec, maximum QRS interval \>=140 msec, maximum QTCF interval (Fridericia's correction) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, maximum increase of \>=25 percent for baseline values of \>200 msec and \>=50 percent for baseline values of \<=200 msec for PR interval, maximum increase from baseline of \>=50 percent for QRS interval, maximum increase from baseline of \>=30 msec to \<60 msec and maximum increase from baseline of \>60 msec in QTCF interval (Fridericia's Correction).
| participants | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| Part 2: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities | 0 | 0 |
Criteria: Hemoglobin; hematocrit; red blood cell count: \<0.8\*lower limit of normal, (LLN), mean corpuscular volume; mean corpuscular hemoglobin concentration; mean platelet volume:\<0.9\*LLN or \>1.1\* upper limit of normal (ULN), platelet: \<0.5\*LLN or \>1.75\*ULN, white blood cells \<0.6\*LLN or \>1.5\*ULN, lymphocyte; neutrophil: \<0.8\*LLN or \>1.2\*ULN, basophil; eosinophil; monocyte:\>1.2\*ULN, bilirubin (total, direct, indirect) \>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase:\>3.0\*ULN, total protein; albumin:\<0.8\*LLN or \>1.2\*ULN; creatinine: \>1.3\*ULN, uric acid\>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride; calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN, glucose \<0.6\*LLN or \>1.5\*ULN, urine specific gravity \<1.003, urine pH \<4.5 or \>8, urine glucose or ketones (qualitative) \>=1, urine protein; urine blood/hemoglobin \>=1, urobilinogen; bilirubin; nitrite; leukocyte esterase \>=1.
| participants | Cohort 1- No CYP3A5*1 Alleles | Cohort 2- One CYP3A5*1 Allele | Cohort 3- Two CYP3A5*1 Alleles | Cohort 4- No CYP3A5*1 Alleles |
|---|---|---|---|---|
| Part 1: Number of Participants With Laboratory Abnormalities | 1 | 5 | 0 | 2 |
Criteria: Hemoglobin; hematocrit; red blood cell count: \<0.8\*LLN, mean corpuscular volume; mean corpuscular hemoglobin concentration; mean platelet volume: \<0.9\*LLN or \>1.1\*ULN, platelet: \<0.5\*LLN or \>1.75\*ULN, white blood cells \<0.6\*LLN or \>1.5\*ULN, lymphocyte; neutrophil: \<0.8\*LLN or \>1.2\*ULN, basophil; eosinophil; monocyte: \>1.2\*ULN, bilirubin (total, direct, indirect) \>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase: \>3.0\*ULN, total protein; albumin: \<0.8\*LLN or \>1.2\*ULN; creatinine: \>1.3\*ULN, uric acid \>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride; calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN, glucose \<0.6\*LLN or \>1.5\*ULN, urine specific gravity \<1.003, urine pH \<4.5 or \>8, urine glucose or ketones (qualitative) \>=1, urine protein; urine blood/hemoglobin \>=1, urobilinogen; bilirubin; nitrite; leukocyte esterase \>=1.
| participants | Cohort 1- No CYP3A5*1 Alleles | Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|
| Part 2: Number of Participants With Laboratory Abnormalities | 1 | 3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohort 1- No CYP3A5*1 Alleles | — | 0/11 (0%) | 3/11 (27.3%) |
| Part 1: Cohort 2- One CYP3A5*1 Allele | — | 0/12 (0%) | 0/12 (0%) |
| Part 1: Cohort 3- Two CYP3A5*1 Alleles | — | 0/12 (0%) | 0/12 (0%) |
| Part 1: Cohort 4 - No CYP3A5*1 Alleles | — | 0/12 (0%) | 3/12 (25%) |
| Part 2: Cohort 1- No CYP3A5*1 Alleles | — | 0/11 (0%) | 2/11 (18.2%) |
| Part 2: Cohort 3- Two CYP3A5*1 Alleles | — | 0/12 (0%) | 1/12 (8.3%) |
| Event | Part 1: Cohort 1- No CYP3A5*1 Alleles | Part 1: Cohort 2- One CYP3A5*1 Allele | Part 1: Cohort 3- Two CYP3A5*1 Alleles | Part 1: Cohort 4 - No CYP3A5*1 Alleles | Part 2: Cohort 1- No CYP3A5*1 Alleles | Part 2: Cohort 3- Two CYP3A5*1 Alleles |
|---|---|---|---|---|---|---|
| PollakiuriaRenal and urinary disorders | 0/11 | 0/12 | 0/12 | 2/12 | 0/11 | 0/12 |
| Dry mouthGastrointestinal disorders | 1/11 | 0/12 | 0/12 | 0/12 | 1/11 | 0/12 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/11 | 0/12 | 0/12 | 0/12 | 1/11 | 0/12 |
| FlatulenceGastrointestinal disorders | 1/11 | 0/12 | 0/12 | 1/12 | 0/11 | 0/12 |
| PainGeneral disorders | 1/11 | 0/12 | 0/12 | 0/12 | 0/11 | 0/12 |
| PolyuriaRenal and urinary disorders | 1/11 | 0/12 | 0/12 | 0/12 | 0/11 | 0/12 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/11 | 0/12 | 0/12 | 0/12 | 0/11 | 0/12 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/11 | 0/12 | 0/12 | 0/12 | 0/11 | 0/12 |
| Hot flushVascular disorders | 1/11 | 0/12 | 0/12 | 0/12 | 0/11 | 0/12 |
| Abdominal pain upperGastrointestinal disorders | 0/11 | 0/12 | 0/12 | 0/12 | 1/11 | 0/12 |
Safety analysis set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Part 1 and Part 2: Cohort 1 -No CYP3A5*1 Alleles | Part 1: Cohort 2 - One CYP3A5*1 Allele | Part 1 and 2: Cohort 3 - Two CYP3A5*1 Alleles | Part 1: Cohort 4 - No CYP3A5*1 Alleles | Total |
|---|---|---|---|---|---|
| Mean | 37.3 ± 9.7 | 38.3 ± 10.4 | 34.6 ± 11.4 | 48.2 ± 6 | 39.6 ± 10.6 |
| Sex: Female, Male(Participants) | Part 1 and Part 2: Cohort 1 -No CYP3A5*1 Alleles | Part 1: Cohort 2 - One CYP3A5*1 Allele | Part 1 and 2: Cohort 3 - Two CYP3A5*1 Alleles | Part 1: Cohort 4 - No CYP3A5*1 Alleles | Total |
|---|---|---|---|---|---|
| Female | 2 | 0 | 1 | 1 | 4 |
| Male | 9 | 12 | 11 | 11 | 43 |
Ran from Nov 2015 to primary completion in Mar 2016, 4 months.
Results were first posted in Apr 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Maraviroc · Cobicistat mixture with darunavir